321 related articles for article (PubMed ID: 32099991)
1. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
Lake JE; Wu K; Bares SH; Debroy P; Godfrey C; Koethe JR; McComsey GA; Palella FJ; Tassiopoulos K; Erlandson KM
Clin Infect Dis; 2020 Dec; 71(9):e471-e477. PubMed ID: 32099991
[TBL] [Abstract][Full Text] [Related]
2. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV.
Burns JE; Stirrup OT; Dunn D; Runcie-Unger I; Milinkovic A; Candfield S; Lukha H; Severn A; Waters L; Edwards S; Gilson R; Pett SL
AIDS; 2020 Jan; 34(1):109-114. PubMed ID: 31567162
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy.
Erlandson KM; Wu K; Lake JE; Samuels DC; Bares SH; Tassiopoulos K; Koethe JR; Brown TT; Leonard M; Benson CA; Haas DW; Hulgan T;
AIDS; 2021 Mar; 35(3):439-445. PubMed ID: 33252493
[TBL] [Abstract][Full Text] [Related]
4. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
5. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.
Kerchberger AM; Sheth AN; Angert CD; Mehta CC; Summers NA; Ofotokun I; Gustafson D; Weiser SD; Sharma A; Adimora AA; French AL; Augenbraun M; Cocohoba J; Kassaye S; Bolivar H; Govindarajulu U; Konkle-Parker D; Golub ET; Lahiri CD
Clin Infect Dis; 2020 Jul; 71(3):593-600. PubMed ID: 31504324
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens.
Wu K; Koethe J; Hulgan T; Brown T; Bares SH; Tassiopoulos K; Lake JE; Leonard M; Samuels DC; Erlandson K; Haas DW
Pharmacogenet Genomics; 2024 Feb; 34(2):25-32. PubMed ID: 37910437
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
Leonard MA; Cindi Z; Bradford Y; Bourgi K; Koethe J; Turner M; Norwood J; Woodward B; Erdem H; Basham R; Baker P; Rebeiro PF; Sterling TR; Hulgan T; Daar ES; Gulick R; Riddler SA; Sinxadi P; Ritchie MD; Haas DW
Clin Infect Dis; 2021 Oct; 73(7):e2153-e2163. PubMed ID: 32829410
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
9. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
10. Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV.
Lahiri CD; Mehta CC; Sykes C; Weiser SD; Palella F; Lake JE; Mellors JW; Gustafson D; French AL; Adimora AA; Konkle-Parker D; Sharma A; Bolivar H; Kassaye SG; Rubin LH; Alvarez JA; Golub ET; Ofotokun I; Sheth AN
AIDS Res Hum Retroviruses; 2023 Dec; 39(12):644-651. PubMed ID: 37140468
[TBL] [Abstract][Full Text] [Related]
11. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
12. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus.
Chow W; Donga P; Côté-Sergent A; Rossi C; Lefebvre P; Lafeuille MH; Emond B; Hardy H
Curr Med Res Opin; 2020 Aug; 36(8):1313-1323. PubMed ID: 32459155
[TBL] [Abstract][Full Text] [Related]
13. Real-world experience with weight gain among pregnant women living with HIV who are using integrase inhibitors.
Fuller T; Fragoso da Silveira Gouvêa MI; Benamor Teixeira ML; Ferreira Medeiros A; Amorim da Silva P; Medeiros Braga C; Constan Werneck Sant'anna M; de Mattos Salgueiro M; da Silveira Bressan C; Mendes-Silva W; João EC
HIV Med; 2023 Mar; 24(3):301-310. PubMed ID: 36065478
[TBL] [Abstract][Full Text] [Related]
14. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.
Lahiri CD; Xu Y; Wang K; Alvarez JA; Sheth AN; O'Halloran J; Spence AB; Tien P; Gustafson DR; Milam J; Fischl MA; Konkle-Parker D; Adimora AA; Sharma A; Weber KM; Ofotokun I; Rubin LH
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):461-467. PubMed ID: 33231474
[TBL] [Abstract][Full Text] [Related]
15. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
[TBL] [Abstract][Full Text] [Related]
16. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
17. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV.
Erlandson KM; Mohaweche R; Morrow M; Mawhinney S; Khuu V; Boyd M; Balasubramanyam A; Melanson EL; Lake JE
J Antimicrob Chemother; 2024 Jan; 79(1):179-185. PubMed ID: 38000089
[TBL] [Abstract][Full Text] [Related]
18. No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults.
Burns JE; Stirrup O; Waters L; Dunn D; Gilson R; Pett SL
HIV Med; 2022 Mar; 23(3):294-300. PubMed ID: 34634168
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women.
Summers NA; Lahiri CD; Angert CD; Aldredge A; Mehta CC; Ofotokun I; Kerchberger AM; Gustafson D; Weiser SD; Kassaye S; Konkle-Parker D; Sharma A; Adimora AA; Bolivar H; Cocohoba J; French AL; Golub ET; Sheth AN
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):355-362. PubMed ID: 33060420
[TBL] [Abstract][Full Text] [Related]
20. Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide.
Palella FJ; Hou Q; Li J; Mahnken J; Carlson KJ; Durham M; Ward D; Fuhrer J; Tedaldi E; Novak R; Buchacz K
J Acquir Immune Defic Syndr; 2023 Jan; 92(1):67-75. PubMed ID: 36150045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
